How deadly is Prostate cancer?

Zenbateraino da hilgarria prostatako minbizia?

Prostatako minbizia gizonen bigarren minbizi ohikoena da mundu osoan, 2018an 1.276 milioi kasu berri zenbatu ziren, gizonen minbizi kasu guztien % 7,1 ordezkatzen dutenak.

Prostatako minbiziaren heriotza-tasa ere altua da, 2018. urtean mundu osoan 37.005 heriotza estimatu baitira.

Hala ere, heriotza-tasa oso desberdina da eskualdearen arabera, Mendebaldeko Afrikak prostata minbiziaren heriotza-arriskuaren bosgarren maila du munduan, eta Nigeriak eskualde honetako biztanleria eta ekonomia handiena du.

Nigerian, prostatako minbizia da gizonen artean minbizi ohikoena eta hilgarriena, gutxi gorabehera 32,8 kasu eta 16,3 heriotza 100.000 gizoneko.

Ipar Amerikako heriotza-tasaren bikoitza da.

Gaixotasuna berandu detektatzeak, detekziorako eta detekziorako baliabide mugatuek, eta kasuen dokumentazio eta jakinarazpen murriztuak, Nigeriako heriotza-tasa altuari laguntzen diote.

Estatu Batuetan, prostatako minbizia da gizonezkoen minbiziaren heriotzaren bigarren arrazoirik ohikoena, urtero gutxi gorabehera 40.000 gizon hiltzen baitira gaixotasunagatik.

Prostatako minbiziaren heriotza-tasa poliki-poliki murrizten ari da 1990eko hamarkadaren hasieratik, baina osasun-arazo garrantzitsua izaten jarraitzen du.

Orokorrean, prostatako minbizia gaixotasun hilgarria da, batez ere arreta medikoa eta azterketa baliabideak mugatuak dituzten eskualdeetan.

Hala ere, detekzio goiztiarrak eta tratamenduak nabarmen hobetu ditzakete emaitzak eta heriotza-tasak murriztu.

Erreferentziak

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.

Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.

Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.

Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.

Erantzukizunik ez: medikoak.

Webgune hau hezkuntza eta informazio helburuetarako bakarrik eskaintzen da eta ez du aholkularitza medikoa edo zerbitzu profesionalik eskaintzen.

Ematen den informazioa ez da osasun-arazo edo gaixotasun bat diagnostikatzeko edo tratatzeko erabili behar, eta aholku mediko pertsonala bilatzen dutenek baimendutako mediku batekin kontsultatu behar dute.

Kontuan izan galderen erantzunak sortzen dituen sare neuronalak ez duela zehaztasunik, batez ere, eduki numerikoari dagokionez. Adibidez, gaixotasun jakin bat duten pertsonen kopurua.

Beti bilatu zure medikuaren aholkua edo beste osasun-zerbitzu kualifikatu bat gaixotasun mediko bati buruz. Sekula ez baztertu aholku mediko profesionala edo atzeratu webgune honetan irakurri duzun zerbaitengatik. Larrialdi mediko bat izan dezakezula uste baduzu, deitu 911 edo joan berehala larrialdietako gelara. Webgune honek edo haren erabilerak ez du mediku-paziente harremana sortzen. Ez BioMedLibek, ez bere langileek, ez webgune honetako inork ez du inolako adierazpenik egiten, espresorik edo inpliziturik, hemen emandako informazioari edo haren erabilerari dagokionez.

Arduragabekeria: egile eskubideak

1998ko Digital Millennium Copyright Act-ek, 17 U.S.C. § 512 (DMCA) -k, egile eskubideen jabeek Interneten agertzen den materialak AEBetako egile eskubideen arabera dituzten eskubideak urratzen dituela uste duten errekurtsoak eskaintzen ditu.

Fede onez uste baduzu gure webgunearekin edo zerbitzuekin lotuta eskuragarri dagoen eduki edo material batek zure egile eskubideak urratzen dituela, zuk (edo zure agenteak) jakinarazpen bat bidal diezagukezu eduki edo materiala kentzeko edo sarbidea blokeatzeko eskatuz.

Jakinarazpenak idatziz bidali behar dira posta elektronikoz (ikus "Kontaktua" atala posta elektronikoaren helbideari buruz).

DMCAk eskatzen du egile eskubideak urratzeari buruzko jakinarazpenean honako informazioa jasotzea: (1) urratzeari buruzko lanaren deskribapena; (2) urratzeari buruzko edukiaren deskribapena eta eduki hori aurkitzea ahalbidetzeko behar beste informazio; (3) zure harremanetarako informazioa, zure helbidea, telefono zenbakia eta posta elektronikoaren helbidea barne; (4) zure adierazpena, sinesmen ona duzula, salatutako moduan dagoen edukia ez dela egile eskubideen jabeak, edo bere agenteak, edo edozein legearen eraginez baimenduta.

(5) zure adierazpen bat, zin faltsuaren zigorraren pean sinatua, jakinarazpenean dagoen informazioa zehatza dela eta urratu direla dioten egile eskubideak betearazteko eskumena duzula;

eta (6) egile eskubideen jabearen edo egile eskubideen jabearen izenean jarduteko baimena duen pertsonaren sinadura fisikoa edo elektronikoa.

Goian aipatutako informazio guztia ez emateak zure kexaren tramitazioa atzeratzea ekar dezake.

Harremanetan jartzea

Bidali iezaguzu mezu elektroniko bat edozein galdera edo iradokizunekin.

How deadly is prostate cancer?

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.

The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.

However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.

In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.

This is more than double the death rate in North America.

Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.

In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.

The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.

Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.

However, early detection and treatment can significantly improve outcomes and reduce mortality rates.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.